You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema
SBC: ADEPTHERA, LLC Topic: NCIDESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies
SBC: ZMK Medical Technologies, Inc. Topic: NCIThis proposal is a collaborative effort between Yale University and the medical device company Eigen to develop a more robust and accurate method for the deformable fusion of pre-operative magnetic resonance images (MRI) and intra-procedure trans-rectal ultrasound (TRUS) images to guide prostate biopsy. Prostate cancer is a major cause of death in the U.S. and biopsy is the gold-standard for its d ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Novel Treatment for Glioblastoma
SBC: CURTANA PHARMACEUTICALS INC Topic: NCI? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeting of Myc-Max dimerization for the treatment of cancer
SBC: SORRENTO THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: NIDADESCRIPTION (provided by applicant): During this STTR program, Electronic BioSciences (EBS) proposes to develop a nanopore based system around our University of Utah collaborators newly developed technology that will be capable of identifying and quantifying sequence specific RNA modifications. A system capable of quantitative, low cost, high throughput, RNA modification characterization has the c ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Cathepsin Inhibitors for Treatment of Breast Cancer Induced Bone Pain
SBC: VIROBAY, INC. Topic: NCIDESCRIPTION (provided by applicant): The World Health Organization estimates that the number of women living with breast cancer globally will rise to 15 million by the year 2020 with a significant portion of these patients in advanced stages of the disease. Breast cancer is the most frequent malignant tumor in women in the U.S. with nearly 200,000 women diagnosed each year. The U.S. NIH estimate o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Lateral Flow Immunoassays For Pharmacokinetic Dosing Of Monoclonal Antibodies
SBC: ABREOS BIOSCIENCES, INC. Topic: NCIDESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are used to treat a variety of cancers and other diseases. Dosing is typically based on body surface area, but population pharmacokinetic (PK) data suggests considerable variation across patients. Furthermore, there is growing evidence that patients with low final trough levels of circulating antibody have a poorer outcome, suggestin ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Efficacy of Silicon-based Dual Energy CT Contrast Material
SBC: NEXTRAST, INC Topic: NIDDKDESCRIPTION (provided by applicant): Our long term goal is to revolutionize the safety and effectiveness of computed tomography (CT) imaging for millions of Americans across a broad range of gastrointestinal disease. Bowel and intravenous contrast materials improve the CT imaging of abdominal disease. Unfortunately, none of the current clinical contrast materials are visibly different from the oth ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Manufacture of Self-Reporting, Drug Loaded Porous Silicon Nanomaterials for Treat
SBC: SPINNAKER BIOSCIENCES, INC. Topic: NEIPROJECT SUMMARY/ABSTRACT Visual impairment is a global epidemic affecting millions of individuals currently. A large portion of these individuals suffer from chronic age-related macular degeneration (AMD), characterized by progressive neovascularization and vascular leakage near the central region (macula) of the retina. Current treatments for AMD, including laser photocoagulation, photodynamic th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High Z Oraya Therapy for wet AMD
SBC: ORAYA THERAPEUTICS, INC Topic: NEIProject Description The purpose of this project is to develop a new radiotherapy treatment modality that will substantially enhance the treatment of wet AMD with minimal toxicity to healthy tissue, leading to major improvement in visual acuity, decreaseduse of intravitreal injections of anti-VEGF agents, lower cost of treatment, and a substantially improved quality of life for patients. The new m ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health